Article Data

  • Views 1511
  • Dowloads 111

Case Report

Open Access

Human protein C concentrate in a patient with meningitis and bleeding as a complication of treatment with recombinant activated protein C

  • SERGIO COLOMBO1
  • MARTINA CRIVELLARI1
  • MILENA MUCCI 1
  • VALENTINA PLUMARI1
  • PAOLO SILVANI1
  • PATRIZIA DELLA VALLE2
  • ARMANDO D’ANGELO2
  • ALBERTO ZANGRILLO1

1,Department of Anesthesia and Intensive Care San Raffaele Scientific Institute

2,Coagulation Service & Thrombosis Research Unit San Raffaele Scientific Institute

DOI: 10.22514/SV81.052013.12 Vol.8,Issue 1,May 2013 pp.62-64

Published: 01 May 2013

*Corresponding Author(s): MARTINA CRIVELLARI E-mail: crivellari.martina@hsr.it

Abstract

Some case reports suggest that protein C zymogen supplementation may improve the outcome of patients with congenital or acquired protein C deficiency, such as sepsis-induced purpura fulminans. We describe the case report of a patient suf-fering from meningitis who developed a bleeding complication after recombinant human activated protein C administration and was successfully treated without any further bleeding complication with protein C concentrate.

Protein C concentrate can be considered in adult patients with meningitis, even if at risk or in the presence of bleeding.

Keywords

sepsis, purpura fulmi-nans, protein C, bleeding

Cite and Share

SERGIO COLOMBO,MARTINA CRIVELLARI,MILENA MUCCI ,VALENTINA PLUMARI,PAOLO SILVANI,PATRIZIA DELLA VALLE,ARMANDO D’ANGELO,ALBERTO ZANGRILLO. Human protein C concentrate in a patient with meningitis and bleeding as a complication of treatment with recombinant activated protein C. Signa Vitae. 2013. 8(1);62-64.

References

1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker M. Surviving sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2008;36:296-327.

2. Bernard GR, Vincent JL, Laterre PF, La Rosa SP, Lopez-Rodriguez A. The Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. New Engl J Med 2001;344:699-709.

3. Ranieri M, Thompson TB, Barbie PS, Dhainaut JF, Douglas IS, Finfer S, et al. For the PROWESS-SHOCK Study Group. Drotrecogin Alfa (Activated) in Adults with Septic Shock. N Engl J Med 2012;366:2055-64.

4. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000;96:3719–24.

5. De Kleijn ED, De Groot R, Hack CE, H Mulder PG, Engl W, Moritz B, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003;31:1839-47.

6. Baratto F, Michielan F, Meroni M, Dal Palù A, Boscolo A, Ori C. Protein C concentrate to restore physiological values in adult septic patients. Intensive Care Med 2008;34:1707-12.

7. Crivellari M, Della Valle P, Landoni G, Pappalardo F, Gerli B, Bignami E, et al. Human protein C zymogen concentrate in patients with severe sepsis and multiple organ failure after adult cardiac surgery. Intensive Care Med 2009;35:1959–63.

8. Dhainaut JF, Yan SB, Claessens YE. Protein C/activated protein C pathway: Overview of clinical trial results in severe sepsis. Crit Care Med 2004;32:S194-201.

9. Fisher CJ, Yan SB. Protein C levels as prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000;28 Suppl 9:S49-56.

10. Landoni G, Crivellari M, Monti G, Gerli C, Silvani P, Zangrillo A. Human protein C concentrates in adult septic patients. Signa vitae 2008;3(2):13-7.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top